Journey Medical Reports Q2 Earnings with Improved Financials and Growth in Emrosi Prescriptions
Journey Medical (DERM) reported second-quarter earnings for 2026 showing a significant improvement, including positive EBITDA of $1.4 million compared to a loss the previous year. The company's total revenue reached $18.5 million, up 23% from last year, driven by strong performance in its Emrosi product line. Emrosi netted $8.1 million in revenue with prescription volume and unique prescribers increasing significantly since late 2025. The company also noted a narrowing GAAP net loss to just $0.3 million or $0.01 per share, down from $3.8 million the prior year. Management highlighted improved payer reimbursement rates and commercial access for Emrosi covering nearly all U.S. commercial lives. Despite these gains, management acknowledged ongoing challenges such as insurance deductible resets affecting Qbrexza performance in early 2026 and potential barriers like prior authorizations impacting broader adoption of Emrosi.
